{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:50:57Z","timestamp":1788274257260,"version":"build-2803163510"},"reference-count":16,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Approximately 15% of deaths in adults with sickle cell disease (SCD) are attributed to kidney failure. Although urine albumin-to-creatinine ratio (UACR) is recommended to screen for kidney damage, its utility in predicting long-term complications in SCD remains unclear. We investigated whether \u201cKidney Disease: Improving Global Outcomes (KDIGO)\u201d algorithms used to assess kidney disease in the general population predicted chronic kidney disease (CKD) progression and mortality in a longitudinal cohort of 379 adults with SCD from 2 academic institutions. KDIGO criteria include UACR detected in 2 consecutive measurements \u22653 months apart and a heat map integrating UACR with estimated glomerular filtration rate. KDIGO-defined CKD was present in 39.8% of individuals in our SCD cohort. Over a median follow-up of 3.3 years, incremental KDIGO-defined UACR category independently predicted a twofold greater risk of CKD progression and 1.8-fold greater risk of mortality (P \u2264 .05). KDIGO-defined CKD heat map strengthened the ability to predict CKD progression and mortality risk (P \u2264 .0087). Our data provide clinical support for the screening utility of UACR based on repeated abnormal values \u22653 months apart. The KDIGO heat map further refines the risk of long-term outcomes among adults with SCD and should be applied to guide future studies for monitoring and intervention strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017204","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T20:07:52Z","timestamp":1755634072000},"page":"5610-5615","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["KDIGO-defined kidney dysfunction predicts long-term outcomes in a multicenter cohort of adults with sickle cell disease"],"prefix":"10.1182","volume":"9","author":[{"given":"Xu","family":"Zhang","sequence":"first","affiliation":[{"name":"1Division of Hematology & Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0574-1604","authenticated-orcid":false,"given":"Michael R.","family":"DeBaun","sequence":"additional","affiliation":[{"name":"2Department of Pediatrics, Vanderbilt-Meharry Center of Excellence in Sickle Cell Disease, Vanderbilt University, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Wuichet","sequence":"additional","affiliation":[{"name":"2Department of Pediatrics, Vanderbilt-Meharry Center of Excellence in Sickle Cell Disease, Vanderbilt University, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-7195","authenticated-orcid":false,"given":"Rima","family":"Zahr","sequence":"additional","affiliation":[{"name":"3Department of Pediatric Nephrology and Hypertension, The University of Tennessee Health Science Center, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3185-1786","authenticated-orcid":false,"given":"Zalaya","family":"Ivy","sequence":"additional","affiliation":[{"name":"1Division of Hematology & Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell J.","family":"Weiss","sequence":"additional","affiliation":[{"name":"4Department of Hematology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex G.","family":"Bick","sequence":"additional","affiliation":[{"name":"5Division of Genetic Medicine, Vanderbilt University, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4725-7295","authenticated-orcid":false,"given":"Victor R.","family":"Gordeuk","sequence":"additional","affiliation":[{"name":"1Division of Hematology & Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8584-4194","authenticated-orcid":false,"given":"Santosh L.","family":"Saraf","sequence":"additional","affiliation":[{"name":"1Division of Hematology & Oncology, Department of Medicine, University of Illinois Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"1","key":"2025111014320987600_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/ajh.21569","article-title":"Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease","volume":"85","author":"Fitzhugh","year":"2010","journal-title":"Am J Hematol"},{"issue":"6","key":"2025111014320987600_bib2","doi-asserted-by":"crossref","first-page":"e2024067341","DOI":"10.1542\/peds.2024-067341","article-title":"Trends in sickle cell disease mortality: 1979-2020","volume":"154","author":"Karkoska","year":"2024","journal-title":"Pediatrics"},{"issue":"4","key":"2025111014320987600_bib3","first-page":"1135","article-title":"Treatment patterns and burden of complications associated with sickle cell disease: A US retrospective claims analysis","volume":"3","author":"Manwani","year":"2022","journal-title":"Eur J Haematol"},{"issue":"9","key":"2025111014320987600_bib4","first-page":"1121","article-title":"The economic burden of end-organ damage among Medicaid patients with sickle cell disease in the United States: a population-based longitudinal claims study","volume":"26","author":"Campbell","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"issue":"23","key":"2025111014320987600_bib5","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease. Life expectancy and risk factors for early death","volume":"330","author":"Platt","year":"1994","journal-title":"N Engl J Med"},{"issue":"11","key":"2025111014320987600_bib6","doi-asserted-by":"crossref","first-page":"e79923","DOI":"10.1371\/journal.pone.0079923","article-title":"Severe painful vaso-occlusive crises and mortality in a contemporary adult sickle cell anemia cohort study","volume":"8","author":"Darbari","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"2025111014320987600_bib7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.md.0000189089.45003.52","article-title":"Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients","volume":"84","author":"Powars","year":"2005","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"2025111014320987600_bib8","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1111\/bjh.18494","article-title":"Patients with sickle cell disease who develop end-stage kidney disease continue to experience poor survival - a 19-year United States renal data system study","volume":"199","author":"Winer","year":"2022","journal-title":"Br J Haematol"},{"issue":"3","key":"2025111014320987600_bib9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bjh.12024","article-title":"High one year mortality in adults with sickle cell disease and end-stage renal disease","volume":"159","author":"McClellan","year":"2012","journal-title":"Br J Haematol"},{"issue":"4S","key":"2025111014320987600_bib10","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease Improving Global Outcomes KDIGO CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"issue":"23","key":"2025111014320987600_bib11","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1182\/bloodadvances.2019000916","article-title":"American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease","volume":"3","author":"Liem","year":"2019","journal-title":"Blood Adv"},{"issue":"15","key":"2025111014320987600_bib12","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1182\/bloodadvances.2022008692","article-title":"Creating an automated contemporaneous cohort in sickle cell anemia to predict survival after disease-modifying therapy","volume":"7","author":"Cronin","year":"2023","journal-title":"Blood Adv"},{"issue":"19","key":"2025111014320987600_bib13","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"2025111014320987600_bib14","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/ajh.26264","article-title":"Risk factors for CKD stage II onset in a prospective cohort of homozygous sickle cell adults","volume":"96","author":"Roger","year":"2021","journal-title":"Am J Hematol"},{"issue":"7","key":"2025111014320987600_bib15","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/bloodadvances.2019001378","article-title":"Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study","volume":"4","author":"Niss","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"2025111014320987600_bib16","first-page":"e326","article-title":"CKD quality improvement intervention with PCMH integration: health plan results","volume":"25","author":"Vassalotti","year":"2019","journal-title":"Am J Manag Care"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/21\/5610\/2419087\/blooda_adv-2025-017204-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/21\/5610\/2419087\/blooda_adv-2025-017204-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T19:32:13Z","timestamp":1762803133000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/21\/5610\/546762\/KDIGO-defined-kidney-dysfunction-predicts-long"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":16,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017204","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,11]]},"published":{"date-parts":[[2025,11,3]]}}}